Latest News

In a major scientific breakthrough, a drug used to treat Parkinson’s and related diseases may be able to delay or prevent age-related macular degeneration (AMD), the most common form of blindness among older Americans.

A research team, supported in part by BrightFocus Foundation, wanted to know whether patients who received the drug L-DOPA as treatment for Parkinson’s or other diseases were protected from AMD. After combing through massive amounts of medical chart data, their answer is yes.

Learn about a BrightFocus grantee's role in confirming amyloid's role in early Alzheimer's, a record-breaking $5.9 million in new Alzheimer's research awarded by BrightFocus Foundation, how to be prepared if you need to search for someone who has Alzheimer's disease, and more, in the winter edition of our Alzheimer's disease newsletter.

Explore the mystery of normal-tension glaucoma, a medication that may reduce the risk of open-angle glaucoma, learn about 15 new glaucoma research grants awarded by BrightFocus Foundation, and more in the fall edition of our glaucoma newsletter.

Research by BrightFocus grantee Matthew Campbell, PhD, of Trinity College Dublin, represents a potential new way to help clear the brain of a build-up of the toxic amyloid beta (Aβ) that leads to Alzheimer’s.

World Alzheimer’s Day finds us at a crossroads. We are confronted by a mounting global health and economic crisis. But we are also seeing encouraging signs from our laboratories, local communities, and halls of government.

Researchers funded by BrightFocus Foundation are bringing us closer to preventing the spread of Alzheimer’s disease in the brain. Learn more about this exciting research.

Brian Elderton joins BrightFocus Foundation as Vice President for Development. He brings more than 25 years of senior leadership experience with higher education and health care institutions.

Seven BrightFocus grantees had their research chosen as a “Hot Topic” by the ARVO Scientific Program Committee. Read about their exciting work.